Business View Magazine | November 2019

15 BUSINESS VIEW MAGAZINE NOVEMBER 2019 A necdotally, it is well known that cannabis has the potential to kill cancer cells. It is also well known that no two people have the same genetic makeup. Finding the best possible match became the challenge for Cannabics Pharmaceuticals Inc. (CNBX). By introducing modern precisions medicine through personalized assessment tools, Cannabics is helping to move cannabinoids into the future of cancer therapy. Bringing the promises of the healing power of cannabis to cancer patients today. This amazing work is being undertaken by a dedicated group of experts at the Cannabics Pharmaceuticals U.S. Head Office in Bethesda, Maryland, and Israeli locations in Tel-Aviv (Corporate Offices) and Rehovot (Lab). Business View recently asked the Cannabics team about Cannabics Pharmaceuticals Inc. The healing power of cannabis the company’s operations, biggest challenges, and how they plan to achieve their passionate mission to advance cancer treatment options. The following is an edited transcript of their responses: BVM: Could you give us some background on your company and an overview of your niche in the U.S. and global cannabis industries? CNBX: “Cannabics Pharmaceuticals Inc. is a U.S. public company developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid- based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to provide physicians with the insight they need to more effectively